Table 1.
Participant Characteristics
| Variable | All (n=82) | Men (n=61) | Women (n=21) |
|---|---|---|---|
| Age, y | 63.8±11.8 | 62.4±11.9 | 67.7±10.7 |
| Height, m | 173.8±8.7 | 176.2±7.1 | 166.6±8.9a |
| Weight, kg | 86.6±17.9 | 89.6±17.5 | 78.1±16.9a |
| BSA, m2 | 2.0±0.2 | 2.1±0.2 | 1.9±0.2a |
| BMI, kg/m2 | 28.6±5.2 | 28.7±4.7 | 28.2±6.7 |
| Hypertension, n (%) | 40 (49%) | 31 (51%) | 9 (43%) |
| Diabetes mellitus, n (%) | 4 (5%) | 3 (5%) | 1 (5%) |
| Dyslipidemia, n (%) | 36 (44%) | 31 (51%) | 5 (24%)a |
| Smoking, n (%) | 48 (58%) | 34 (56%) | 14 (67%) |
| β‐Blocker use, n (%) | 26 (32%) | 20 (32%) | 6 (29%) |
| Aneurysm location (root/ascending aorta) | 24/58 | 24/37 | 0/21a |
| dTAA/hTAA | 47/35 | 36/25 | 11/10 |
| Baseline imaging modality | |||
| Echocardiogram, n (%) | 16 (20%) | 12 (20%) | 4 (19%) |
| CT, n (%) | 58 (70%) | 41 (67%) | 17 (81%) |
| MRI, n (%) | 8 (10%) | 8 (13%) | 0a |
| Concordant imaging modality, n (%) | 47 (57%) | 36 (59%) | 11 (52%) |
| Baseline aneurysm size, mm | 45.6±4.3 | 45.8±4.0 | 45.1±5.1 |
| Indexed baseline aneurysm size, mm/m2 | 22.9±3.0 | 22.4±2.6 | 24.5±3.5a |
| Follow‐up time, y | 3.1±2.8 | 2.9±2.5 | 3.7±3.5 |
| Most recent aneurysm size, mm | 47.2±4.1 | 46.9±3.8 | 48.1±4.6 |
| Indexed most recent aneurysm size, mm/m2 | 23.8±3.0 | 23.0±2.6 | 26.1±3.0a |
| TAA growth rate, mm/y | 0.74±0.85 | 0.59±0.66 | 1.19±1.15a |
| Indexed TAA growth rate, (mm/m2)/y | 0.38±0.45 | 0.29±0.32 | 0.65±0.65a |
Concordant imaging modality was defined as the same imaging modality used in the first and last imaging studies. BMI indicates body mass index; BSA, body surface area; CT, computed tomography; dTAA, degenerative thoracic aortic aneurysm; hTAA, heritable thoracic aortic aneurysm; MRI, magnetic resonance imaging; TAA, thoracic aortic aneurysm.
a
P≤0.05 when compared to men.